Acadia Pharmaceuticals Set to Join S&P SmallCap 600

(Moderate)

(Neutral)

Rhea-AI Summary

Acadia Pharmaceuticals (NASD: ACAD) will be added to the S&P SmallCap 600 prior to the opening of trading on Jan 3, 2025, replacing Independent Bank Group (NASD: IBTX).

The change follows an announced acquisition involving SouthState (NYSE: SSB) and is effective before the market open on the stated date. For details, see S&P Dow Jones Indices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

What This Means

This announcement highlights Acadia’s forthcoming addition to the S&P SmallCap 600 on January 3, 202...

Analysis

This announcement highlights Acadia’s forthcoming addition to the S&P SmallCap 600 on January 3, 2025, replacing Independent Bank Group following its pending acquisition. Index inclusion can broaden the shareholder base through passive and benchmark-driven strategies and may affect trading liquidity over time. In context of prior mixed price reactions to positive updates, investors may watch how ownership disclosures, trading volumes, and subsequent fundamental news evolve after the index change becomes effective.

Key Figures

Effective date: Jan 3, 2025

1 metrics

Effective date Jan 3, 2025 Date ACAD joins S&P SmallCap 600

Historical Context

5 past events · Latest: Apr 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	Product availability	Positive	-1.0%	DAYBUE STIX formulation became broadly available for Rett syndrome patients.
Mar 12	Conference participation	Neutral	-3.1%	Participation in Stifel 2026 Virtual CNS Forum fireside chat and webcast.
Mar 03	Board appointment	Positive	+4.0%	Appointment of Jonathan M. Poole to the Board and Audit Committee.
Mar 02	Regulatory setback	Negative	-1.4%	Negative CHMP opinion on trofinetide with planned re-examination request.
Feb 25	Earnings results	Positive	-1.3%	Reported Q4 and FY2025 revenue growth with FY2026 revenue guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive or strategic news often saw flat-to-negative next-day moves, while negative regulatory news aligned with modest declines.

Recent Company History

Over the last several months, Acadia reported multiple milestones, including Q4/FY2025 revenues of $284M and $1.07B, broader U.S. availability of DAYBUE STIX for Rett syndrome, and participation in a CNS-focused investor forum. The company also faced a negative CHMP opinion on trofinetide but planned a re-examination, and strengthened governance with a new board appointment. Price reactions have frequently been muted or negative even after seemingly positive updates, which frames the S&P SmallCap 600 addition as another potentially important but not guaranteed price-moving catalyst.

Regulatory & Risk Context

Short Interest: 11.02%

Short Interest

11.02% of float

0% 15% 30%+

moderate as of 2026-05-29 Days to cover: 8.08

Key Terms

s&p smallcap 600, s&p midcap 400, gics sector

3 terms

s&p smallcap 600 technical

"Jan 3, 2025 | S&P SmallCap 600 | Addition | Acadia Pharmaceuticals | ACAD"

A stock market index made up of 600 small-cap U.S. companies chosen to represent the performance of smaller publicly traded firms. It matters to investors because it acts like a temperature gauge for the small-company segment of the market, serving as a benchmark for fund managers, a basis for index funds and ETFs, and a way to compare returns and risk when building a diversified portfolio.

s&p midcap 400 technical

"S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring"

The S&P MidCap 400 is a group of 400 companies that are smaller than the big, well-known corporations but larger than tiny startups. It helps investors see how medium-sized companies are performing in the stock market, acting like a barometer for this middle-sized group of businesses.

gics sector technical

"Ticker | GICS Sector"

GICS sector is one of the major industry groupings from the Global Industry Classification Standard, a system that sorts companies into consistent categories (like Technology or Health Care) based on the primary business they do. Investors use these sectors like folders in a filing cabinet to compare companies, build diversified portfolios, and track how whole parts of the market are performing rather than focusing on single stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

12/30/2024 - 05:37 PM

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

Following is a summary of the change that will take place prior to the open of trading on the effective date:

Effective Date	Index Name	Action	Company Name	Ticker	GICS Sector
Jan 3, 2025	S&P SmallCap 600	Addition	Acadia Pharmaceuticals	ACAD	Health Care
Jan 3, 2025	S&P SmallCap 600	Deletion	Independent Bank Group	IBTX	Financials

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

SOURCE S&P Dow Jones Indices

FAQ

What does Acadia Pharmaceuticals (ACAD) joining the S&P SmallCap 600 mean for shareholders on Jan 3, 2025?

ACAD's addition means inclusion in the S&P SmallCap 600 index starting Jan 3, 2025, potentially raising index-tracker demand. According to S&P Dow Jones Indices, ACAD replaces Independent Bank Group (IBTX) effective prior to the open on that date.

Why is Independent Bank Group (IBTX) being removed from the S&P SmallCap 600 on Jan 3, 2025?

IBTX is being deleted because it is being acquired by SouthState (SSB), prompting index reconstitution. According to S&P Dow Jones Indices, IBTX will be removed prior to the market open on Jan 3, 2025.

Will the S&P SmallCap 600 change for Acadia (ACAD) affect trading at the market open on Jan 3, 2025?

The index change is effective prior to the opening on Jan 3, 2025, so inclusion will be reflected at the market open. According to S&P Dow Jones Indices, ACAD will be added and IBTX deleted before trading begins.

How should investors confirm the S&P SmallCap 600 reconstitution involving Acadia (ACAD) on Jan 3, 2025?

Investors should verify index changes via S&P Dow Jones Indices and official market notices ahead of Jan 3, 2025. According to S&P Dow Jones Indices, ACAD is scheduled for addition and IBTX for deletion prior to the open.

Does the press release mention the role of SouthState (SSB) in the index change involving Independent Bank Group (IBTX)?

Yes. The release notes SouthState (SSB) is acquiring Independent Bank Group, which is the reason for IBTX's removal. According to S&P Dow Jones Indices, the acquisition is expected to close soon pending final conditions.